236 related articles for article (PubMed ID: 28604788)
1. Long-term efficacy and safety of nalfurafine hydrochloride on pruritus in chronic liver disease patients: Patient-reported outcome based analyses.
Kamimura K; Yokoo T; Kamimura H; Sakamaki A; Abe S; Tsuchiya A; Takamura M; Kawai H; Yamagiwa S; Terai S
PLoS One; 2017; 12(6):e0178991. PubMed ID: 28604788
[TBL] [Abstract][Full Text] [Related]
2. Is patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? A post-marketing, single-arm, prospective study.
Yagi M; Tanaka A; Namisaki T; Takahashi A; Abe M; Honda A; Matsuzaki Y; Ohira H; Yoshiji H; Takikawa H;
J Gastroenterol; 2018 Oct; 53(10):1151-1158. PubMed ID: 29663077
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of a novel ĸ-agonist for managing intractable pruritus in dialysis patients.
Kumagai H; Ebata T; Takamori K; Miyasato K; Muramatsu T; Nakamoto H; Kurihara M; Yanagita T; Suzuki H
Am J Nephrol; 2012; 36(2):175-83. PubMed ID: 22868684
[TBL] [Abstract][Full Text] [Related]
4. Shorter pruritus period and milder disease stage are associated with response to nalfurafine hydrochloride in patients with chronic liver disease.
Kawano T; Atsukawa M; Tsubota A; Shimada N; Toyoda H; Takaguchi K; Tani J; Morishita A; Hiraoka A; Mikami S; Ishikawa T; Okubo H; Watanabe T; Okubo T; Arai T; Hayama K; Itokawa N; Kondo C; Iwakiri K
Sci Rep; 2022 May; 12(1):7311. PubMed ID: 35508514
[TBL] [Abstract][Full Text] [Related]
5. Clinical Profiles of Nalfurafine Hydrochloride for the Treatment of Pruritus Patients.
Miyamoto Y; Oh T; Aihara E; Ando A
Handb Exp Pharmacol; 2022; 271():455-472. PubMed ID: 33201326
[TBL] [Abstract][Full Text] [Related]
6. Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study.
Kumagai H; Ebata T; Takamori K; Muramatsu T; Nakamoto H; Suzuki H
Nephrol Dial Transplant; 2010 Apr; 25(4):1251-7. PubMed ID: 19926718
[TBL] [Abstract][Full Text] [Related]
7. Nalfurafine hydrochloride: a new drug for the treatment of uremic pruritus in hemodialysis patients.
Nakao K; Mochizuki H
Drugs Today (Barc); 2009 May; 45(5):323-9. PubMed ID: 19584962
[TBL] [Abstract][Full Text] [Related]
8. Nalfurafine hydrochloride, a selective κ opioid receptor agonist, has no reinforcing effect on intravenous self-administration in rhesus monkeys.
Nakao K; Hirakata M; Miyamoto Y; Kainoh M; Wakasa Y; Yanagita T
J Pharmacol Sci; 2016 Jan; 130(1):8-14. PubMed ID: 26786553
[TBL] [Abstract][Full Text] [Related]
9. One year long-term study on abuse liability of nalfurafine in hemodialysis patients.
Ueno Y; Mori A; Yanagita T
Int J Clin Pharmacol Ther; 2013 Nov; 51(11):823-31. PubMed ID: 24040851
[TBL] [Abstract][Full Text] [Related]
10. Systemic kappa opioid receptor agonists in the treatment of chronic pruritus: a literature review.
Phan NQ; Lotts T; Antal A; Bernhard JD; Ständer S
Acta Derm Venereol; 2012 Sep; 92(5):555-60. PubMed ID: 22504709
[TBL] [Abstract][Full Text] [Related]
11. Nalfurafine hydrochloride for the treatment of pruritus.
Inui S
Expert Opin Pharmacother; 2012 Jul; 13(10):1507-13. PubMed ID: 22663138
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo pharmacological characterization of the main metabolites of nalfurafine hydrochloride.
Nakao K; Togashi Y; Honda T; Momen S; Umeuchi H; Sakakibara S; Tanaka T; Okano K; Mochizuki H
Eur J Pharmacol; 2012 Nov; 695(1-3):57-61. PubMed ID: 22981641
[TBL] [Abstract][Full Text] [Related]
13. Pruritus is common in patients with chronic liver disease and is improved by nalfurafine hydrochloride.
Yoshikawa S; Asano T; Morino M; Matsumoto K; Kashima H; Koito Y; Miura T; Takahashi Y; Tsuboi R; Ishii T; Otake H; Fujiwara J; Sekine M; Uehara T; Yuhashi K; Matsumoto S; Asabe S; Miyatani H; Mashima H
Sci Rep; 2021 Feb; 11(1):3015. PubMed ID: 33542298
[TBL] [Abstract][Full Text] [Related]
14. Effect of nalfurafine hydrochloride on pruritus and anxiety level in hemodialysis patients.
Inui S; Shirakawa Y; Itami S
J Dermatol; 2012 Oct; 39(10):886-7. PubMed ID: 22142516
[No Abstract] [Full Text] [Related]
15. [Pharmacological effects of nalfurafine hydrochloride, a kappa-opioid receptor agonist].
Nakao K; Hasebe K; Yoshikawa S; Ikeda K; Hirakata M; Miyamoto Y; Mochizuki H
Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Nov; 30(5-6):185-91. PubMed ID: 21226314
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and Severity of Itching in Patients with End-Stage Renal Disease: Treatment with Nalfurafine Hydrochloride.
Nakamoto H; Kobayashi T; Noguchi T; Kusano T; Ashitani K; Imaeda H; Maezono M
Blood Purif; 2019; 47 Suppl 2():45-49. PubMed ID: 30943482
[TBL] [Abstract][Full Text] [Related]
17. Spontaneous scratching behavior in MRL/lpr mice, a possible model for pruritus in autoimmune diseases, and antipruritic activity of a novel kappa-opioid receptor agonist nalfurafine hydrochloride.
Umeuchi H; Kawashima Y; Aoki CA; Kurokawa T; Nakao K; Itoh M; Kikuchi K; Kato T; Okano K; Gershwin ME; Miyakawa H
Eur J Pharmacol; 2005 Aug; 518(2-3):133-9. PubMed ID: 16055114
[TBL] [Abstract][Full Text] [Related]
18. Dissociable effects of the kappa opioid receptor agonist nalfurafine on pain/itch-stimulated and pain/itch-depressed behaviors in male rats.
Lazenka ML; Moerke MJ; Townsend EA; Freeman KB; Carroll FI; Negus SS
Psychopharmacology (Berl); 2018 Jan; 235(1):203-213. PubMed ID: 29063139
[TBL] [Abstract][Full Text] [Related]
19. Nalfurafine hydrochloride to treat pruritus: a review.
Inui S
Clin Cosmet Investig Dermatol; 2015; 8():249-55. PubMed ID: 26005355
[TBL] [Abstract][Full Text] [Related]
20. Nalfurafine prevents 5'-guanidinonaltrindole- and compound 48/80-induced spinal c-fos expression and attenuates 5'-guanidinonaltrindole-elicited scratching behavior in mice.
Inan S; Dun NJ; Cowan A
Neuroscience; 2009 Sep; 163(1):23-33. PubMed ID: 19524022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]